###begin article-title 0
###xml 16 19 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
SIRT1 Regulates HIV Transcription via Tat Deacetylation
###end article-title 0
###begin article-title 1
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A New Paradigm in Eukaryotic Biology: HIV Tat and the Control of Transcriptional Elongation
###end article-title 1
###begin article-title 2
###xml 40 43 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Novel Enzyme Shows Potential as an Anti-HIV Target
###end article-title 2
###begin p 3
###xml 4 32 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
###xml 389 392 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 590 593 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 663 668 <span type="species:ncbi:10090">mouse</span>
###xml 826 829 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The human immunodeficiency virus (HIV) Tat protein is acetylated by the transcriptional coactivator p300, a necessary step in Tat-mediated transactivation. We report here that Tat is deacetylated by human sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent class III protein deacetylase in vitro and in vivo. Tat and SIRT1 coimmunoprecipitate and synergistically activate the HIV promoter. Conversely, knockdown of SIRT1 via small interfering RNAs or treatment with a novel small molecule inhibitor of the SIRT1 deacetylase activity inhibit Tat-mediated transactivation of the HIV long terminal repeat. Tat transactivation is defective in SIRT1-null mouse embryonic fibroblasts and can be rescued by expression of SIRT1. These results support a model in which cycles of Tat acetylation and deacetylation regulate HIV transcription. SIRT1 recycles Tat to its unacetylated form and acts as a transcriptional coactivator during Tat transactivation.
###end p 3
###begin p 4
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cycles of Tat acetylation and deacetylation, mediated by human sirtuin 1 (SIRT1), regulate HIV transcription suggesting that SIRT1 could be a therapeutic target
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b01">1</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b02">2</xref>
###xml 19 49 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 153 156 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 488 491 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The Tat protein of human immunodeficiency virus 1 (HIV-1) is essential for the transcriptional activation of the integrated HIV-1 provirus. Without Tat, HIV transcriptional elongation is inefficient and results in abortive transcripts that cannot support viral replication [1,2]. Tat is produced early after infection from rare full-length genomic transcripts generated despite the elongation defect. These transcripts lead to the synthesis of a few Tat molecules sufficient to stimulate HIV transcription elongation, leading to the production of additional Tat transcripts and protein.
###end p 6
###begin p 7
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b03">3</xref>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b04">4</xref>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b05">5</xref>
###xml 814 815 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b06">6</xref>
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 656 659 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Tat activates HIV transcription through the trans-acting responsive element (TAR), an RNA stem-loop structure that forms at the 5' end of all viral transcripts [3,4]. The TAR stem contains a three-nucleotide bulge structure recognized by the arginine-rich motif (ARM) in Tat (amino acids 49-57). In vivo, Tat binding to TAR requires cyclinT1, a cofactor that interacts cooperatively with both the N-terminal transactivation region of Tat (amino acid 1-48) and loop sequences at the top of the TAR stem-loop structure [5]. CyclinT1, a component of pTEFb (the positive transcription elongation factor b), recruits the cyclin-dependent kinase 9 (CDK9) to the HIV promoter. CDK9 hyperphosphorylates the C-terminal domain of RNA polymerase II, which potently enhances the processivity of the RNA polymerase II complex [6].
###end p 7
###begin p 8
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b07">7</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b08">8</xref>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b09">9</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b10">10</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b12">12</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b13">13</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
We and others have shown that Tat is acetylated at lysine 50 by the transcriptional coactivators p300 and human GCN5 (general control of amino acid synthesis 5) [7,8,9,10]. Tat acetylation is important for Tat activity and defines a critical cyclinT1-independent step in Tat transactivation [11]. Tat acetylated at lysine 50 cannot form a ternary complex with cyclinT1 and TAR RNA. It dissociates from TAR and binds instead to the p300/CREB-binding protein-associated factor (PCAF) via its bromodomain [12,13].
###end p 8
###begin p 9
###xml 260 263 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 440 443 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our current working model is that Tat acetylation disrupts the Tat/TAR/cyclinT1 complex and leads to the transfer of Tat and PCAF to the elongating polymerase. According to this model, both forms of Tat, unacetylated and acetylated, play distinct roles in the HIV promoter transcriptional cycle and lead to the sequential recruitment of the cofactors cyclinT1 and PCAF. Because of the limiting amounts of Tat protein in the early stages of HIV infection and the critical role of unacetylated Tat for pTEFb recruitment to TAR, the question arises whether Tat acetylation can be reverted via a cellular Tat deacetylase.
###end p 9
###begin p 10
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b14">14</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b15">15</xref>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 100 105 <span type="species:ncbi:4932">yeast</span>
###xml 177 182 <span type="species:ncbi:4932">yeast</span>
There are three distinct classes of human histone deacetylases (HDACs) based on their homology with yeast transcriptional repressors. Class I and II HDACs are homologous to the yeast proteins Rpd3p (reduced potassium dependency 3) and Hda1p (histone deacetylase A1), respectively [14,15]. The deacetylase activity of class I and II HDACs is efficiently inhibited by trichostatin A (TSA) and other related hydroxamate-based inhibitors.
###end p 10
###begin p 11
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b16">16</xref>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b17">17</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b18">18</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b19">19</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b20">20</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b21">21</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b22">22</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b23">23</xref>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b24">24</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b25">25</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b26">26</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b26">26</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b27">27</xref>
###xml 923 925 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b28">28</xref>
###xml 1024 1026 1020 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b29">29</xref>
###xml 1153 1155 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b30">30</xref>
###xml 1236 1238 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b31">31</xref>
###xml 1239 1241 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b32">32</xref>
###xml 68 73 <span type="species:ncbi:4932">yeast</span>
###xml 326 331 <span type="species:ncbi:9606">human</span>
Class III HDACs, also named sirtuins (SIRTs), are homologous to the yeast transcriptional repressor silent information regulator 2p (Sir2p) [16]. Sir2p is a TSA-insensitive histone deacetylase that requires nicotinamide adenine dinucleotide (NAD+) as a cofactor [17,18,19]. Seven homologs of Sir2p have been identified in the human genome. Called SIRT1-7, they all contain a highly conserved catalytic domain [20]. Despite their enzymatic activity on histone substrates in vitro, recent experimental evidence suggests that SIRT proteins predominantly target nonhistone proteins for deacetylation, in both the nucleus and the cytoplasm. The nuclear SIRT1 protein deacetylates p53 [21,22,23], TAFI68 (Tata box-binding protein-associated factor I of 68 kDa) [24], PCAF and myoblast determination protein (MyoD) [25], p300 [26] and Forkhead transcription factors [26,27], the p65 subunit of nuclear factor kappa B (NF-kappaB) [28], and the Ku70 telomeric protein (also known as the thyroid autoantigen of 70 kDa or Ku antigen) [29]. The cytoplasmic SIRT2 protein is found associated with the microtubule network and deacetylates lysine 40 of alpha-tubulin [30]. SIRT3 is a mitochondrial matrix protein whose target has not been identified [31,32].
###end p 11
###begin p 12
###xml 180 183 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Here, we identify the class III HDAC SIRT1 as a specific Tat deacetylase and demonstrate that SIRT1 is a novel cofactor necessary for efficient Tat-mediated transactivation of the HIV promoter.
###end p 12
###begin title 13
Results
###end title 13
###begin p 14
###xml 180 188 180 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 574 582 574 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
###xml 681 689 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
###xml 914 922 914 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
###xml 1020 1028 1020 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 790 801 <span type="species:ncbi:3704">horseradish</span>
To test the ability of SIRT1-7 to deacetylate Tat in vitro, we transfected HEK 293 cells with expression vectors for human SIRT1-7 and immunoprecipitated the FLAG-tagged proteins (Figure 1A). The immunoprecipitated material was incubated with a full-length synthetic Tat protein carrying an acetylated lysine at position 50 (AcTat). The extent of Tat deacetylation was determined by Western blot (WB) with antibodies specific for the acetylated ARM in Tat [11]. Incubation of AcTat with immunoprecipitated SIRT1, SIRT2, and SIRT3 resulted in deacetylation of Tat lysine 50 (Figure 1B). These enzymes also deacetylate histones as determined in a standard histone deacetylase assay (Figure 1B). All reactions contained equal amounts of AcTat as determined by immunoblotting with streptavidin-horseradish peroxidase conjugate (SA-HRP), which recognized the biotin label attached to the N terminus of AcTat (SA-HRP in Figure 1B). SIRT enzymes in the reactions were visualized by immunoblotting with FLAG antibodies (FLAG in Figure 1B).
###end p 14
###begin p 15
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b30">30</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b31">31</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b23">23</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b33">33</xref>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b34">34</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b35">35</xref>
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g001">Figure 1</xref>
SIRT2 and SIRT3 proteins are localized primarily in the cytoplasm and the mitochondria [30,31], and SIRT1 resides in the cell nucleus [23,33]. Since Tat is a predominantly nuclear protein, we focused our efforts on SIRT1. The SIRT1-mediated deacetylation of Tat was dependent on NAD+ and completely inhibited by nicotinamide, an inhibitor for class III HDACs [34,35]. TSA, a specific inhibitor of class I and II HDACs, had no effect (Figure 1C). These results demonstrate that the Tat deacetylase activity within immunoprecipitated SIRT1 material can be solely attributed to SIRT1 and not to a contaminating class I or II HDAC.
###end p 15
###begin p 16
###xml 445 453 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 547 555 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 678 686 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 757 765 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 1038 1046 1018 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
To test whether Tat and SIRT1 interact, Tat/FLAG and SIRT1/influenza hemagglutinin (HA) were overexpressed in HEK 293 cells, and cellular lysates subjected to coimmunoprecipitation assays. Tat was detected with an alpha-FLAG antiserum in material immunoprecipitated with SIRT1 by the alpha-HA antibody in cells transfected with SIRT1- and Tat expression vectors, but no signal was obtained when SIRT1 or Tat alone was expressed (IP: alpha-HA in Figure 2A). Conversely, SIRT1 also specifically coimmunoprecipitated with Tat/FLAG (IP: alpha-FLAG in Figure 2A). The same was observed when Tat/T7 was coexpressed with SIRT1/FLAG and was immunoprecipitated with alpha-T7 antibodies (Figure 2B). No coimmunoprecipitation of Tat was observed with SIRT2 and SIRT6 (Figure 2B), two SIRT proteins that can also localize to the cell nucleus (BN and EV, personal communication), or any other SIRT protein (unpublished data). Furthermore, Tat coimmunoprecipitated with endogenous SIRT1 in Tat-expressing, but not in vector-transfected, HEK 293 cells (Figure 2C). No SIRT1- or Tat-specific signals were obtained after immunoprecipitations (IPs) in the absence of alpha-SIRT1 antibodies, excluding nonspecific binding of Tat to the Sepharose beads to which the antibodies were bound.
###end p 16
###begin p 17
###xml 283 291 283 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 582 590 582 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 693 701 693 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
###xml 1128 1136 1128 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g002">Figure 2</xref>
To test whether Tat and SIRT1 interact directly, increasing amounts of biotinylated synthetic Tat (72 amino acids) were incubated with recombinant full-length SIRT1. After pulldown with streptavidin-conjugated agarose, SIRT1 coimmunoprecipitated with Tat in a dose-dependent manner (Figure 2D). Recombinant SIRT1 bound equally well to acetylated and unacetylated synthetic Tat, indicating that the interaction occurred independently of the acetylation state of Tat (Figure 2D). WB with AcTat antibodies showed that AcTat remained acetylated during incubation with the SIRT1 enzyme (Figure 2D). Re-blotting with SA-HRP detected both Tat proteins in equivalent amounts in the binding reactions (Figure 2D). We also tested the ability of a Tat mutant protein (termed TatK50R to indicate mutation of lysine to arginine at position 50 of the Tat protein) to interact with SIRT1. This mutation preserves the basic charge at position 50, but cannot be acetylated. After transfection into HEK 293 cells, TatK50R accumulated to lower concentrations than wild-type Tat, but was bound to SIRT1 efficiently in coimmunoprecipitation assays (Figure 2E). These results collectively indicate that Tat binds SIRT1 directly and independently of lysine 50.
###end p 17
###begin p 18
###xml 211 219 211 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 717 725 705 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 998 1000 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b28">28</xref>
###xml 165 168 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 200 203 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 578 581 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 691 694 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1114 1132 <span type="species:ncbi:11886">Rous sarcoma virus</span>
###xml 1134 1137 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
The effects of SIRT1 on Tat function were assessed after transfection into HeLa cells. SIRT1 modestly, but reproducibly, enhanced Tat-mediated transactivation of an HIV promoter luciferase construct (HIV LTR in Figure 3A). In contrast, expression of a catalytically inactive SIRT1 protein (termed SIRT1H363Y to indicate mutation of histidine to tyrosine at position 363 of the SIRT1 protein) suppressed Tat transactivation in a dominant-negative manner, indicating that the catalytic activity of SIRT1 is necessary for Tat transactivation. Similar results were obtained when an HIV promoter reporter construct containing mutant binding sites for the transcription factor NF-kappaB was used (HIV LTR DeltaNF-kappaB in Figure 3A). This result indicates that the superinduction of Tat activity by wild-type SIRT1 and the suppression of Tat activity by catalytically inactive SIRT1 were dependent on the interaction between SIRT1 and Tat rather than on the interaction between SIRT1 and NF-kappaB/p65 [28]. Importantly, SIRT1 (both wild-type and SIRT1H363Y mutant) had no effect on the transcriptional activity of the Rous sarcoma virus (RSV) LTR, a promoter used to drive Tat expression in these cotransfection experiments.
###end p 18
###begin p 19
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b36">36</xref>
###xml 610 618 610 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 759 767 759 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 954 962 954 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 1138 1146 1138 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 1721 1729 1721 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 1921 1929 1921 1929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g003">Figure 3</xref>
###xml 815 818 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1082 1085 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1806 1809 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The effect of SIRT1 on Tat transactivation was further examined using small interfering RNA (siRNA)-mediated knockdown of SIRT1. HeLa cells were transfected with double-stranded RNA oligonucleotides directed against SIRT1 or against firefly luciferase expressed from the pGL3 vector as a control. All luciferase reporter constructs described in this study are based on the pGL2 vector, which is not affected by GL3 siRNAs (siRNAs directed against firefly luciferase expressed from the pGL3 vector) [36]. Levels of endogenous SIRT1 were markedly reduced at 72 h after transfection of siRNAs specific for SIRT1 (Figure 3B). At that time, a significant decrease in Tat transactivation was noted in cells that had received the SIRT1 siRNA, but not the GL3 siRNA (Figure 3C). The SIRT1 siRNA slightly enhanced the basal HIV promoter activity without Tat, and had no effect on the transcriptional activity of TatK50R, the Tat mutant that cannot be acetylated (Figure 3C). Loss of SIRT1 had no effect on the transcriptional activity of the immediate early promoter of the cytomegalovirus (CMV) used to drive Tat expression in these experiments (Figure 3D). In addition, Tat levels in HeLa cells transfected with SIRT1 siRNAs were comparable to Tat levels detected in cells transfected with GL3 siRNAs as determined by WB (unpublished data). To confirm the specificity of the SIRT1 siRNA, mutant double-stranded siRNA oligonucleotides were generated which contained a two-nucleotide mismatch between the target mRNA for SIRT1 and the antisense strand of the siRNA. Transfection of mutant SIRT1 siRNA did not affect expression of endogenous SIRT1 protein in HeLa cells, indicating that the mutation abrogated SIRT1 mRNA cleavage (Figure 3E). SIRT1 siRNA, but not mutant siRNA, suppressed Tat transactivation of the HIV LTR luciferase construct, confirming that the observed suppression was dependent on the loss of SIRT1 protein (Figure 3F).
###end p 19
###begin p 20
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b37">37</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b38">38</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b39">39</xref>
###xml 753 756 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 763 771 763 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g004">Figure 4</xref>
###xml 852 855 852 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 862 870 862 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g004">Figure 4</xref>
###xml 999 1002 999 1002 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1009 1017 1009 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g004">Figure 4</xref>
###xml 1243 1246 1243 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 1281 1305 1281 1305 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Saccharomyces cerevisiae</named-content>
###xml 1417 1425 1417 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g004">Figure 4</xref>
###xml 220 225 <span type="species:ncbi:10090">mouse</span>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 298 301 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 495 501 <span type="species:ncbi:10090">murine</span>
###xml 582 587 <span type="species:ncbi:9606">human</span>
###xml 657 660 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 730 735 <span type="species:ncbi:9606">human</span>
###xml 824 827 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 918 923 <span type="species:ncbi:9606">human</span>
###xml 1281 1305 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Since SIRT1 only modestly enhanced Tat transactivation in HeLa cells, which already express significant levels of SIRT1, we examined the effect of SIRT1 on Tat transactivation in a SIRT1-negative background. We obtained mouse embryonic fibroblasts (MEFs) derived from SIRT1 knockout mice [37]. The HIV LTR luciferase reporter and the Tat expression vector were introduced into these cells by nuclear microinjections because of their low responsiveness to various transfection protocols. Because murine cyclinT1 does not support Tat transactivation [38,39], an expression vector for human cyclinT1 was included in the microinjections. A 120-fold increase in HIV promoter luciferase activity was detected in the presence of Tat and human cyclinT1 in SIRT1+/+ MEFs (Figure 4A). In contrast, Tat-mediated transactivation of the HIV LTR was reduced in SIRT1-/- MEFs (Figure 4A). Ectopic expression of increasing amounts of human SIRT1 resulted in a dose-dependent increase of Tat transactivation in SIRT1-/- MEFs (Figure 4B). In contrast, transactivation of the 5xUAS promoter by Gal4-VP16 was reduced in response to SIRT1 (Gal4-VP16 is a fusion between the binding domain of the DNA-binding transcription factor required for the activation of the GAL genes in response to galactose in Saccharomyces cerevisiae [termed Gal4], and the activator domain of the herpes simplex virus transactivator protein [designated VP16]) (Figure 4C). These results collectively demonstrate that SIRT1 represents a positive factor for Tat function.
###end p 20
###begin p 21
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b04">4</xref>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b05">5</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b40">40</xref>
###xml 634 642 626 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 850 858 842 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 862 863 854 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b06">6</xref>
###xml 235 238 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 338 341 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
This model was further tested in nuclear microinjection experiments using synthetic full-length Tat and AcTat. Microinjection of increasing amounts of either Tat or AcTat proteins into HeLa cells caused a marked transactivation of the HIV LTR luciferase reporter in a dose-dependent manner (Wt TAR in Figure 5A). AcTat transactivated the HIV promoter approximately 1.5-3-fold better than Tat. Transactivation by Tat and AcTat was dependent on the bulge and loop regions of TAR, indicating that transactivation by both proteins required the formation of an intact Tat/TAR/cyclinT1 complex [4,5,40] (TAR DeltaBulge and TAR DeltaLoop in Figure 5A). In agreement with this conclusion, transactivation by both Tat proteins was inhibited in a dose-dependent manner by 5,6-dichlorobenzimidazole riboside (DRB), a CDK9 inhibitor known to block Tat function (Figure 5B) [6].
###end p 21
###begin p 22
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 703 711 703 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 898 906 898 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 1090 1098 1090 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g005">Figure 5</xref>
###xml 523 526 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 673 676 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 813 816 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 859 862 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1076 1079 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
According to our working model, AcTat represents a second step in the transactivation cycle [11]. Since AcTat cannot form the trimolecular complex with cyclinT1 and TAR RNA in vitro, we hypothesized that AcTat becomes partially deacetylated by the Tat deacetylase upon microinjection. This would allow the initiation of the transactivation process by unacetylated Tat binding to TAR with cyclinT1 and CDK9. To further test this hypothesis, we treated cells with deacetylase inhibitors after microinjection of AcTat and the HIV promoter construct. Treatment with TSA, an inhibitor of class I and II HDACs, enhanced the transcriptional activity of AcTat as well as the basal HIV promoter activity (TSA in Figure 5C). In contrast, nicotinamide, an inhibitor of class III deacetylases, blocked transactivation of the HIV promoter by AcTat while stimulating basal HIV promoter activity (Nicotinamide in Figure 5C). Similarly, knockdown of SIRT1 using siRNA inhibited transcriptional activity of AcTat, while slightly enhancing Tat-mediated or basal transcriptional activity of the HIV promoter (Figure 5D). These results support the model that the transcriptional activity of AcTat depends on deacetylation by SIRT1 in cells.
###end p 22
###begin p 23
###xml 211 224 211 224 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">S. cerevisiae</named-content>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b41">41</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b42">42</xref>
###xml 542 544 542 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 604 612 603 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">Figure 6</xref>
###xml 618 619 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">6</xref>
###xml 845 853 843 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">Figure 6</xref>
###xml 1174 1182 1170 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">Figure 6</xref>
###xml 77 80 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 211 224 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 279 284 <span type="species:ncbi:9606">human</span>
###xml 442 447 <span type="species:ncbi:4932">yeast</span>
###xml 682 685 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 804 807 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 834 837 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1098 1101 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 1163 1166 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
The identification of SIRT1 as an enzyme that catalyzes an important step in HIV transcription suggests that it could be targeted therapeutically. Splitomicin was identified as a small molecule inhibitor of the S. cerevisiae Sir2p protein [41]. While splitomicin did not inhibit human SIRT1, we identified a splitomicin derivative, called HR73, which is structurally related to a previously described inhibitor of Hst1, a homolog of Sir2p in yeast [42]. HR73 effectively inhibited the histone deacetylase activity of SIRT1 in vitro with an IC50 (concentration causing 50% inhibition) of less than 5 muM (Figure 6A and 6B). Treatment of HeLa cells with HR73 suppressed Tat-dependent HIV transcription in a dose-dependent manner (3-fold at approximately 1 muM) after transfection of the Tat vector and the HIV LTR luciferase construct (HIV LTR in Figure 6C). In separate experiments, HR73 induced hyperacetylation of another target of SIRT1, the tumor suppressor p53, at the same concentration (1 muM) (Wei Gu and EV, unpublished data). Importantly, HR73 (1 muM) did not suppress the activity of the RSV LTR, the promoter driving Tat expression in our experiments (RSV LTR in Figure 6C).
###end p 23
###begin p 24
###xml 116 121 116 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4&#8211;3</sub>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 227 232 227 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4&#8211;3</sub>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b43">43</xref>
###xml 379 382 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 834 842 833 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">Figure 6</xref>
###xml 1053 1061 1040 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0030041-g006">Figure 6</xref>
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 489 515 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 726 729 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 823 826 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 900 903 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1034 1037 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1112 1115 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1369 1372 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1456 1461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To examine the effect of HR73 on HIV infection, we generated infectious HIV particles using a molecular clone of HIVNL4-3 that contained the green fluorescent protein (GFP) open reading frame in place of the viral nef gene (HIVNL4-3 is a specific viral isolate) [43]. To restrict analysis to a single infection cycle, this clone also contained a frameshift mutation in the viral env gene. Viral particles were produced by cotransfection with a construct expressing the glycoprotein of the vesicular stomatitis virus (VSV-G). Jurkat T cells were incubated with viral supernatant for at least 18 h, washed to remove extracellular virus, and treated with HR73 (1 muM) or dimethyl sulfoxide (DMSO), as a control. We observed that HIV gene expression was reduced 5-fold in cells treated with HR73 as measured by GFP expression (HIV GFP in Figure 6D). In contrast, GFP expression in cells infected with an HIV-based lentiviral vector expressing GFP from the elongation factor 1alpha (EF-1alpha) promoter was not affected by HR73 treatment (HIV [EF-1alpha] in Figure 6D). These data confirm the selectivity of HR73 for HIV transcription and demonstrate that other steps in the viral life cycle, including reverse transcription, nuclear import, and integration, remain unaffected by HR73. These experiments collectively show that the SIRT1 deacetylase activity is required for HIV gene expression and establish SIRT1 as a potential drug target in the treatment of HIV-1 infection.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 398 401 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 498 501 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our previous work documented that Tat acetylation by p300 at lysine 50 is a necessary step in Tat-mediated transactivation and leads to the recruitment of PCAF to the elongating polymerase. We now report the identification of SIRT1, an NAD+-dependent class III protein deacetylase, as a Tat deacetylase and regulator of Tat activity. Tat and SIRT1 coimmunoprecipitate and synergize to activate the HIV promoter. Conversely, knockdown of SIRT1 via siRNA inhibits Tat-mediated transactivation of the HIV LTR. Tat transactivation is defective in SIRT1-null MEFs and can be rescued by expression of SIRT1.
###end p 26
###begin p 27
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b20">20</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b44">44</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b45">45</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b25">25</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b46">46</xref>
###xml 838 840 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b33">33</xref>
###xml 302 309 <span type="species:ncbi:9031">chicken</span>
Recent observations indicate that SIRT1 can regulate transcription via histone-dependent and -independent mechanisms [20]. Since SIRT1 itself does not bind to DNA directly, targeted deacetylation of histones is thought to occur through its interaction with specific DNA binding factors, such as CTIP2 (chicken ovalbumin upstream promoter-transcription factor-interacting protein 2) [44], members of the hairy-related basic helix-loop-helix repressors (HES1 [hairy and Enhancer-of-split 1] and HEY2 [hairy and Enhancer-of-split related with YRPW motif 2]) [45], the MyoD/PCAF complex [25], and the N-CoR (nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptor) co-repressors [46]. In addition, SIRT1 binds and deacetylates histone H1 and promotes the formation of facultative heterochromatin [33].
###end p 27
###begin p 28
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b21">21</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b22">22</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b23">23</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b47">47</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b22">22</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b21">21</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b22">22</xref>
###xml 851 853 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b48">48</xref>
###xml 978 980 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b23">23</xref>
###xml 981 983 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b49">49</xref>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
SIRT1 also deacetylates nonhistone factors, including the tumor suppressor p53 [21,22,23]. Detailed studies of acetylation of p53 and its regulation by SIRT1 have revealed a number of intriguing parallels to Tat regulation. p53 is acetylated by p300 at multiple lysine residues, including lysine 382, leading to an increased transcriptional activity of p53 [47]. Activation of p53 up-regulates the expression of genes whose products promote cell-cycle exit or apoptosis [22]. Therefore, p300 is a positive regulator of p53 activity, while SIRT1 negatively regulates p53 functions. SIRT1 deacetylation of p53 suppresses the induction of apoptosis and promotes cell survival in response to DNA damage [21,22]. Knockout mice for Sir2alpha show increased p53 acetylation after DNA damage leading to increased thymocyte apoptosis after ionizing radiation [48]. Interestingly, both SIRT1 and p53, and the Tat cofactor cyclinT1, are localized in promyelocytic leukemia protein bodies [23,49]. These unique nuclear substructures represent the natural accumulation sites of promyelocytic leukemia protein and are altered or disrupted in certain tumors and in response to different cellular stresses, including Tat expression (EV, unpublished data).
###end p 28
###begin p 29
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b50">50</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b07">7</xref>
###xml 863 865 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b51">51</xref>
###xml 866 868 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b52">52</xref>
###xml 869 871 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b53">53</xref>
###xml 1095 1097 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b54">54</xref>
###xml 1098 1100 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b55">55</xref>
###xml 1101 1103 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b56">56</xref>
###xml 579 582 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 734 737 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 908 911 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1039 1042 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Interestingly, HDAC1 (a class I HDAC) has also been reported to deacetylate p53 [50], but the relative contributions of both HDAC1 and SIRT1 to p53 deacetylation remain unclear. In a previous study, an enhancement of Tat-mediated transactivation was observed in response to TSA, an inhibitor of class I and II HDACs, and was interpreted as evidence that Tat acetylation is under the control of a class I or II HDAC [7]. However, a positive effect of TSA on Tat-mediated transactivation can occur for a number of reasons that are independent of Tat acetylation levels. First, the HIV promoter can be activated by TSA in the absence of Tat, a phenomenon likely to be mediated by transcription factors responsive to TSA that bind to the HIV LTR, such as Sp1 (stimulatory protein 1), YY1 (Yin Yang 1), Eed (embryonic ectoderm development protein), and NF-kappaB/p65 [51,52,53]. Tat-independent activation of the HIV LTR by TSA has been documented both in vitro using chromatinized templates, and in vivo using cell lines containing integrated HIV genomes defective for Tat-mediated transactivation [54,55,56]. Second, TSA activates many promoters that are used to drive Tat expression in transient transfection experiments, making interpretations of these experiments problematic.
###end p 29
###begin p 30
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b07">7</xref>
###xml 607 610 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have observed that Tat acetylation at lysine 50 is not specifically enhanced in response to TSA [11]. These results are supported by functional experiments with Tat mutants. In cotransfection experiments, enhanced transcriptional activity of Tat in response to TSA is preserved when lysine 50 is replaced by an alanine [7] or an arginine (MO, unpublished data). Although these experiments are complicated by the significant increase in Tat expression (due to the stimulatory role of TSA on Tat expression), they provide evidence that lysine 50 in fact might not be a target for a TSA-sensitive enzyme in HIV transcription.
###end p 30
###begin p 31
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b25">25</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b57">57</xref>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b13">13</xref>
Another system that offers intriguing parallels to our observation is the role of the SIRT1/MyoD/PCAF complex in myogenesis [25]. In this complex, PCAF acetylates both itself and MyoD. SIRT1, in contrast, deacetylates both PCAF and MyoD, leading to a retardation of myogenesis. The negative effect of SIRT1 in the regulation of muscle gene expression plays at two distinct levels. First, SIRT1 induces deacetylation of histones in the promoter regions. Second, SIRT1 deacetylates MyoD, which leads to an inhibition of its transcriptional activity [57]. Our previous experiments documented the specific interaction of acetylated Tat and PCAF via the PCAF bromodomain and the ARM region of Tat and the role of this interaction in Tat transactivation [13]. The possibility that Tat bound to the elongating polymerase and to PCAF is regulated by a PCAF-SIRT1 complex is intriguing and will be further explored.
###end p 31
###begin p 32
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b12">12</xref>
###xml 1046 1048 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b13">13</xref>
###xml 345 348 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In most identified sites of action, SIRT1 showed a negative activity on transcriptional regulatory mechanisms, resulting in an inhibition of target gene expression. In contrast, we have identified a positive regulatory activity of SIRT1 on Tat-mediated transactivation. According to our working model, Tat becomes acetylated at the level of the HIV promoter after binding to TAR. The acetylation of the Tat ARM can potentially affect other biological activities associated with this domain, including RNA binding, nuclear or nucleolar import, and protein stability. Tat acetylation could also be involved in the delivery of Tat to the transcription complex, and/or might moderate interactions with cyclinT1/CDK9 prior to transcription. However, we provided evidence that Tat acetylation leads to a dissociation of Tat from cyclinT1 and TAR and to its transfer to the elongating polymerase [11]. Acetylated Tat, bound to the elongating polymerase, recruits the transcriptional coactivator PCAF via its acetyl group and the bromodomain of PCAF [12,13].
###end p 32
###begin p 33
###xml 495 498 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 663 666 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
An unresolved question raised by this model is the fate of acetylated Tat at the end of the transcription cycle. Since acetylated Tat cannot recruit cyclinT1 to the TAR element, a new transcription cycle would require either the synthesis of a new unacetylated Tat protein or the deacetylation of Tat. Tat concentrations are limiting early in the virus life cycle since Tat expression is under the control of the basal LTR. Tat recycling is therefore likely to represent a rate-limiting step in HIV transcription early during the replicative cycle of the virus. Experiments presented in this manuscript demonstrate that SIRT1 catalyzes this rate-limiting step in HIV transcription.
###end p 33
###begin p 34
###xml 238 239 238 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 406 407 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 492 495 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
These observations raise a number of additional questions. The demonstration that Tat transactivating activity is controlled by SIRT1 connects HIV transcription with the metabolic state of the cell. The HDAC activity of SIRT1 requires NAD+ as a cofactor. NAD+ and its reduced form NADH serve as cofactors in many metabolic and stress reactions involving oxidation and reduction. Changes in the cellular NAD+/NADH ratio may regulate SIRT1 enzymatic activity, Tat transcriptional activity, and HIV replication and pathogenesis.
###end p 34
###begin p 35
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b25">25</xref>
The site of Tat deacetylation is unknown at this point. We hypothesize that the deacetylation could be triggered by molecular events linked with the end of the transcriptional elongation process. Deacetylation of Tat by SIRT1 could lead to its dissociation from the elongating polymerase and from PCAF. The previous demonstration that PCAF and SIRT1 can be coimmunoprecipitated from cells supports this model [25].
###end p 35
###begin p 36
###xml 232 245 232 245 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">S. cerevisiae</named-content>
###xml 80 83 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 232 245 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 674 677 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 756 759 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 879 882 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The identification of SIRT1 as an enzyme that catalyzes a rate-limiting step in HIV transcription suggests that it could be targeted therapeutically. Since our preliminary experiments indicated that splitomicin, an inhibitor of the S. cerevisiae Sir2 enzymatic activity, did not inhibit the mammalian sirtuins, we screened several compounds structurally related to splitomicin for their ability to inhibit the mammalian sirtuins. This process led to the identification of HR73, an inhibitor that suppresses SIRT1 enzymatic activity in vitro at low micromolar concentrations. This inhibitor induced p53 hyperacetylation in vivo (unpublished data) and significantly decreased HIV transcription. These results validate SIRT1 as a novel therapeutic target for HIV infection. Future efforts will analyze in additional molecular detail the role of Tat acetylation and deacetylation in HIV transcription and replication.
###end p 36
###begin title 37
Materials and Methods
###end title 37
###begin title 38

###end title 38
###begin title 39
Cells and plasmids
###end title 39
###begin p 40
###xml 163 165 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b37">37</xref>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b58">58</xref>
###xml 294 296 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 331 333 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b59">59</xref>
###xml 343 357 339 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;NF-&#954;B</sub>
###xml 451 452 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b08">8</xref>
###xml 515 517 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b60">60</xref>
###xml 564 565 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b05">5</xref>
###xml 601 603 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b13">13</xref>
###xml 671 673 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b30">30</xref>
###xml 796 798 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b23">23</xref>
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 264 267 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 403 406 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 420 423 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 488 491 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 610 615 <span type="species:ncbi:9606">human</span>
###xml 708 713 <span type="species:ncbi:9606">human</span>
HeLa, HEK 293, and Jurkat cells (obtained from the American Type Culture Collection, Manassas, Virginia, United States), and wild-type or Sir2alpha knockout MEFs [37] were maintained under standard cell culture conditions. The HIV LTR luciferase plasmid [58], the RSV LTR luciferase construct [11], the 5xUAS luciferase construct [59], the LTRDeltaNF-kappaB-luciferase, the full-length (101 amino acid) CMV-Tat/FLAG and CMV-Tat/T7 expression vectors [8], the full-length (101 amino acid) RSV-Tat expression vector [60], the full-length cyclinT1 expression vector [5], the Gal4-VP16 expression vector [13], the human SIRT1-7 expression vectors with a C-terminal FLAG tag [30], as well as wild-type and mutant human SIRT1 and SIRT1H363Y containing a C-terminal MYC (myelocytomatosis oncogene) tag [23] were previously described.
###end p 40
###begin p 41
###xml 522 525 518 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">223</sub>
###xml 653 656 643 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">230</sub>
###xml 663 666 651 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">231</sub>
###xml 677 680 663 666 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">234</sub>
###xml 167 170 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 383 386 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The SIRT1 cDNA was subcloned to generate a C-terminal HA-tagged fusion in a derivative pcDNA 3.1 (+) backbone (HA vector) by standard PCR-based strategies. The mutant CMV-Tat/FLAG expression vector TatK50R was generated by site-directed mutagenesis with the following primers. Forward, 5'- CCTATGGCAGGAGGAAGCGGAGACAGCG-3' and reverse, 5'- CGCTGTCTCCGCTTCCTCCTGCCATAGG-3'. The mutant HIV LTR luciferase constructs (nucleotides 1-791) were generated by site-directed mutagenesis with the following primers. TAR Deltabulge (T223-->A) forward, 5'- GGTTAGACCAGAACTGAGCCTGGGAGC-3' and reverse, 5'- GCTCCCAGGCTCAGTTCTGGTCTAACC-3'. The TAR Deltaloop mutation (C230-->A, T231-->G, and G234-->T) was generated with the following primers. Forward, 5'- GGTTAGACCAGATCTGAGCAGGGTAGCTCTCTGGCTAACTAGGG-3' and reverse, 5'- CCCTAGTTAGCCAGAGAGCTACCCTGCTCAGATCTGGTCTAACC-3'.
###end p 41
###begin p 42
###xml 4 7 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 249 252 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The CMV-luciferase construct was generated by cloning the firefly luciferase gene as a HindIII/BamHI fragment obtained from pGL2 Basic (Promega, Madison, Wisconsin, United States) into pcDNA3.1 (Invitrogen, Carlsbad, California, United States). The CMV-GFP expression plasmid is commercially available (Clontech, Palo Alto, California, United States).
###end p 42
###begin title 43
Synthesis of Tat and HR73
###end title 43
###begin p 44
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b13">13</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b61">61</xref>
Synthesis of 72-amino acid Tat proteins was as described [11,13]. HR73 was synthesized starting from Phenylmeldrum's acid and 6-bromo-1-dimethylaminomethyl-2-naphthol as described [61]. Identity and purity were assured by mass, infrared, and NMR spectroscopy as well as by elemental analysis.
###end p 44
###begin title 45
In vitro Tat deacetylation assay
###end title 45
###begin p 46
###xml 632 633 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 839 841 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 1032 1033 1020 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1273 1275 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b11">11</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 1242 1248 <span type="species:ncbi:9986">rabbit</span>
Human SIRT1-7 FLAG-tagged plasmids were transfected in HEK 293 cells with Lipofectamine reagent (Invitrogen). Cells were lysed 24 h after transfection with lysis buffer (50 mM Tris-HCl [pH 7.5], 0.5 mM EDTA, 0.5% NP40, and 150 mM NaCl) in the presence of protease inhibitors (Roche Molecular Biochemicals, Indianapolis, Indiana, United States). Equal amounts of total proteins were immunoprecipitated with alpha-FLAG M2 agarose (Sigma, St Louis, Missouri, United States), for 2 h at 4 degreesC. Immunoprecipitated material was washed twice with IP buffer and one time with SIRT deacetylation buffer (50 mM Tris-HCl [pH 9], 4 mM MgCl2, and 0.2 mM DTT). The beads were resuspended in 100 mul of SIRT deacetylation buffer containing 1 mug synthetic Tat (72 amino acids) carrying an N-terminal biotin label and an acetyl group at position 50 [11]. Reactions containing TSA (400 nM; WACO Bioproducts, Richmond, Virginia, United States) or nicotinamide (5 mM; Sigma) were preincubated for 10 min at room temperature. After addition of NAD+ (1 mM), reactions were incubated for 2 h at room temperature with constant agitation. Reactions were stopped by the addition of SDS loading buffer, boiled, and after brief centrifugation, analyzed by WB with rabbit alpha-AcTat antibodies [11] or SA-HRP (Jackson Immunoresearch Laboratories, West Grove, Pennsylvania, United States). SIRT1-7 proteins were detected with polyclonal alpha-FLAG antibodies (Sigma).
###end p 46
###begin p 47
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b30">30</xref>
###xml 234 235 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 263 264 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 317 319 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b62">62</xref>
###xml 572 573 571 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 664 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
The histone deacetylation assay with recombinant SIRT1 (1-1.3 U/reaction; Biomol, Plymouth Meeting, Pennsylvania, United States) was performed as described previously for SIRT2 [30] in 100 mul of SIRT deacetylase buffer containing NAD+ (Sigma) and enzymatically [3H]-acetylated histone H3 peptide (amino acids 1-24) [62]. Splitomicin (a gift from Julian Simon, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States) and HR73 in DMSO were added to the reactions at the indicated concentrations with all components of the reactions in the absence of NAD+ for 10 min at room temperature prior to the initiation of the reaction by addition of NAD+ (1 mM).
###end p 47
###begin title 48
Coimmunoprecipitation experiments
###end title 48
###begin p 49
###xml 336 337 336 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 74 77 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 88 91 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 102 105 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1106 1109 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1126 1129 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1214 1220 <span type="species:ncbi:9986">rabbit</span>
###xml 1432 1438 <span type="species:ncbi:9986">rabbit</span>
HEK 293 cells were cotransfected in duplicate with expression vectors for CMV-Tat/FLAG; CMV-Tat/T7 or CMV-TatK50R/FLAG; and the SIRT1/HA or SIRT1-, SIRT2-, and SIRT6-FLAG expression vectors or the respective empty vector controls using Lipofectamine reagent (Invitrogen). Cells were lysed after 24 h in 250 mM NaCl, 0.1% NP40, 20 mM NaH2PO4 (pH 7.5), 5 mM EDTA, 30 mM sodium pyrophosphate, 10 mM NaF, and protease inhibitors (Roche Molecular Biochemicals). Duplicates were pooled, and 1 mg of lysate was immunoprecipitated either with monoclonal alpha-HA (Roche Molecular Biochemicals) together with protein G-Sepharose (Amersham Biosciences, Piscataway, New Jersey, United States) with alpha-FLAG M2 agarose (Sigma) or alpha-T7-agarose (Amersham Biosciences) for 2 h at 4 degreesC. Beads were washed three times in lysis buffer, boiled in SDS loading buffer, and analyzed by WB with polyclonal alpha-FLAG (Sigma), monoclonal alpha-HA (Roche), or monoclonal alpha-T7 (Novagen, Madison, Wisconsin, United States) antibodies. For the IP of Tat with endogenous SIRT1, HEK 293 cells were transfected only with CMV-Tat/FLAG or the CMV-empty vector using Lipofectamine reagent. Cell lysates were immunoprecipitated with rabbit alpha-SIRT1 antibodies (generated against amino acids 506-747) together with protein G-Sepharose (Amersham Biosciences). Immunoprecipitated material was analyzed by WB with the M2 alpha-FLAG antibody (Sigma) or rabbit alpha-SIRT1 antibodies.
###end p 49
###begin p 50
###xml 453 459 <span type="species:ncbi:9986">rabbit</span>
For in vitro interactions, 10 U of recombinant SIRT1 (Biomol) was incubated with biotinylated synthetic Tat or acetylated Tat proteins (0, 0.25, 1, and 4 mug) together with streptavidin-Sepharose (Amersham Biosciences) in lysis buffer in the presence of 5 mM nicotinamide (Sigma) for 3 h at 4 degreesC. Pelleted beads were washed three times in lysis buffer, resuspended in SDS loading buffer, and analyzed by WB with polyclonal alpha-SIRT1 antibodies, rabbit alpha-AcARM, or SA-HRP (Jackson Immunoresearch Laboratories).
###end p 50
###begin title 51
RNAi and transfection experiments
###end title 51
###begin p 52
###xml 1049 1051 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b55">55</xref>
###xml 537 540 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 611 614 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 858 861 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 886 889 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 916 919 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 954 957 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Double-stranded siRNAs directed against nucleotides 408-428 in the SIRT1 mRNA or control GL3 siRNAs (both Dharmacon Research, Lafayette, Colorado, United States) were transfected into HeLa cells plated in six-well plates with Oligofectamine reagent according to the manufacturer's guidelines (Invitrogen). The mutant SIRT1 siRNA was identical to SIRT1 siRNA except for a two-nucleotide mismatch between the target mRNA for SIRT1 and the antisense strand of siRNA at nucleotides 418 and 419. After 48 h, cells were retransfected with the HIV LTR luciferase construct (200 ng) together with increasing amounts of CMV-Tat expression vectors (0, 50, 100, 200, 400, and 800 ng in GL3/SIRT1 siRNA experiments; 0, 2, 20, and 200 ng in SIRT1/mutant SIRT1 siRNA experiments) and corresponding amounts of empty pcDNA3.1 vector (Invitrogen). In the control experiment, CMV-Tat was replaced by the CMV-luciferase construct, and HIV LTR luciferase was replaced by an HIV LTR promoter construct driving the expression of chloramphenicol acetyl transferase (CAT) [55]). Cells were harvested 24 h later and either processed for luciferase assays (Promega) or WB of total cell extracts with polyclonal alpha-SIRT1 or alpha-actin (MP Biochemicals, Aurora, Ohio, United States) antibodies.
###end p 52
###begin p 53
###xml 190 204 190 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;NF-&#954;B</sub>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 37 40 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 50 53 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 143 146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 260 263 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 364 367 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 388 391 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 421 424 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 470 473 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 559 562 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 600 603 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 700 703 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
In cotransfection experiments, human CMV-SIRT1 or CMV-SIRT1H363Y (600 ng) was cotransfected into HeLa cells plated in six-well plates with the HIV LTR luciferase reporter (200 ng) or the LTRDeltaNF-kappaB-luciferase reporter (200 ng) and increasing amounts of RSV-Tat (0, 2, 20, and 200 ng) using the Lipofectamine reagent (Invitrogen). In the control experiment, RSV-Tat was replaced by RSV-luciferase (200 ng), and the HIV LTR luciferase construct was replaced by the HIV LTR CAT reporter. In transfections with HR73, HeLa cells were cotransfected with the HIV LTR luciferase reporter (200 ng) and RSV-Tat expression vectors (0, 20, and 200 ng) or the empty vector using Lipofectamine reagent. The RSV-luciferase construct was used as described above. After 4 h incubation with the DNA/Lipofectamine mix, the culture medium was changed and supplemented with indicated concentrations of HR73 dissolved in DMSO or DMSO alone. Cells were harvested 8 h later and processed for luciferase assays.
###end p 53
###begin title 54
Microinjection experiments
###end title 54
###begin p 55
###xml 344 347 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 411 414 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 457 460 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 484 487 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 529 532 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 954 957 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1015 1018 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Subconfluent MEFs (70%) were grown on Cellocate coverslips (Eppendorf, Westbury, New York, United States), and nuclear microinjections were performed at room temperature with an automated injection system (Eppendorf Micromanipulator 5171 together with Eppendorf Transjector 5246). Samples were prepared as a 20 mul injection mix containing the HIV LTR luciferase reporter or 5xUAS luciferase (each 100 ng/mul), RSV-Tat (10 ng/mul) or Gal4-VP16 (50 ng/mul), CMV-cyclinT1 (100 ng/mul), CMV-SIRT1 (100 or 300 ng/mul), together with CMV-GFP (50 ng/mul) in sterile water. At 6 h after microinjection, cells were examined under a Nikon Eclipse TE300 inverted fluorescent microscope (Nikon, Tokyo, Japan) to determine the number of GFP-positive cells, washed in cold phosphate buffer, and stored at -70 degreesC for luciferase assays (Promega). In HeLa cells, synthetic Tat or AcTat proteins (each 30 or 100 ng/mul) were coinjected with the wild-type or mutant HIV LTR luciferase reporters (each 100 ng/mul) together with CMV-GFP (50 ng/mul), and harvested 4 h after injection. Cells were treated immediately after injection with DRB (10 or 50 muM; Sigma), TSA (400 nM), or nicotinamide (5 mM). Microinjections in siRNA-treated cells were performed 48 h after siRNA transfection.
###end p 55
###begin title 56
Viral infection experiments
###end title 56
###begin p 57
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">env</italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b43">43</xref>
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 648 650 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b63">63</xref>
###xml 793 795 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b64">64</xref>
###xml 980 981 968 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 564 569 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 737 740 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 832 835 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 972 975 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV molecular clone HIV-R7/E-/GFP containing the GFP open reading frame in place of the nef gene and a frameshift mutation in the env gene, as well as the method to generate pseudotyped viral particles with VSV-G, were previously described [43]. The number of infective particles per milliliter was established by infecting 3 x 105 Jurkat cells with different amounts of viral suspension. The titer of the viral stock was measured by flow cytometric analysis of GFP expression 48 h after infection. The pHR'-EF-1alpha/GFP construct is a minimal nonreplicative HIV-1 genome containing a heterologous promoter, EF-1alpha, driving GFP expression [63]. Viral particles were produced by cotransfection of the VSV-G-encoding pMD.G and the HIV-based packaging vector pCMVDeltaR8.91 as described [64]. All vectors for the production of HIV-based lentiviral vectors were provided by Didier Trono, University of Geneva, Switzerland. Jurkat T cells were incubated overnight with HIV-R7/E-/GFP or pHR'-EF-1alpha/GFP viral particles at a theoretical multiplicity of infection of 0.5 in 24-well plates. Cells were repeatedly washed and resuspended in fresh medium containing HR73 (1 muM) or DMSO alone. Viral infection was monitored 36 h later by flow cytometry analysis using a Calibur FACScan (Becton Dickinson, Palo Alto, California, United States).
###end p 57
###begin p 58
We thank K Jones, B Spiegelman, H Poepperl, T Kouzarides, D Trono, J Simon, J Denu, and members of the Verdin and Ott labs for sharing their reagents and expertise, and H zur Hausen and W Greene for helpful discussions. We thank J Carroll and C Goodfellow for graphics, G Howard and S Ordway for editorial advice, and S Sande for administrative assistance. SP is a recipient of a fellowship from the Ministerio de Educacion, Cultura y Deporte, Spain. This work was supported by the Gladstone Institutes (MO and EV), and by NIH grants (to EV and MO). EV is a senior scholar of the Ellison Medical Foundation.
###end p 58
###begin p 59
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product
###end article-title 61
###begin article-title 62
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 94 99 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
In vitro formation of short RNA polymerase II transcripts that terminate within the HIV-1 and HIV-2 promoter-proximal downstream regions
###end article-title 62
###begin article-title 63
###xml 55 60 <span type="species:ncbi:9606">human</span>
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat
###end article-title 63
###begin article-title 64
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat trans-activation requires the loop sequence within tar
###end article-title 64
###begin article-title 65
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA
###end article-title 65
###begin article-title 66
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro
###end article-title 66
###begin article-title 67
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat transcriptional activity is regulated by acetylation
###end article-title 67
###begin article-title 68
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity
###end article-title 68
###begin article-title 69
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones
###end article-title 69
###begin article-title 70
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat
###end article-title 70
###begin article-title 71
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation
###end article-title 71
###begin article-title 72
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain
###end article-title 72
###begin article-title 73
Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain
###end article-title 73
###begin article-title 74
Histone deacetylases (HDACs): Characterization of the classical HDAC family
###end article-title 74
###begin article-title 75
Class II histone deacetylases: Versatile regulators
###end article-title 75
###begin article-title 76
The molecular biology of the SIR proteins
###end article-title 76
###begin article-title 77
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
###end article-title 77
###begin article-title 78
The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases
###end article-title 78
###begin article-title 79
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family
###end article-title 79
###begin article-title 80
Sirtuins: Sir2-related NAD-dependent protein deacetylases
###end article-title 80
###begin article-title 81
Negative control of p53 by Sir2alpha promotes cell survival under stress
###end article-title 81
###begin article-title 82
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
###end article-title 83
###begin article-title 84
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</sub>
Acetylation of TAFI68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription
###end article-title 84
###begin article-title 85
Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state
###end article-title 85
###begin article-title 86
Mammalian SIRT1 represses forkhead transcription factors
###end article-title 86
###begin article-title 87
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
###end article-title 87
###begin article-title 88
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase
###end article-title 88
###begin article-title 89
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
###end article-title 89
###begin article-title 90
###xml 41 42 41 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase
###end article-title 90
###begin article-title 91
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase
###end article-title 91
###begin article-title 92
###xml 9 14 <span type="species:ncbi:9606">human</span>
SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin
###end article-title 93
###begin article-title 94
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Role of NAD+ in the deacetylase activity of the SIR2-like proteins
###end article-title 94
###begin article-title 95
###xml 96 101 <span type="species:ncbi:4932">yeast</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1
###end article-title 95
###begin article-title 96
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
###end article-title 96
###begin article-title 97
The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis
###end article-title 97
###begin article-title 98
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 129 135 <span type="species:ncbi:10090">murine</span>
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein
###end article-title 98
###begin article-title 99
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat
###end article-title 99
###begin article-title 100
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation
###end article-title 100
###begin article-title 101
Identification of a small molecule inhibitor of Sir2p
###end article-title 101
###begin article-title 102
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 98 103 <span type="species:ncbi:4932">yeast</span>
Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast
###end article-title 102
###begin article-title 103
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
###end article-title 103
###begin article-title 104
###xml 48 55 <span type="species:ncbi:9031">chicken</span>
Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression
###end article-title 104
###begin article-title 105
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression
###end article-title 105
###begin article-title 106
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma
###end article-title 106
###begin article-title 107
Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation
###end article-title 107
###begin article-title 108
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice
###end article-title 108
###begin article-title 109
###xml 15 20 <span type="species:ncbi:9606">human</span>
Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein
###end article-title 109
###begin article-title 110
Deacetylation of p53 modulates its effect on cell growth and apoptosis
###end article-title 110
###begin article-title 111
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 42 77 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1
###end article-title 111
###begin article-title 112
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane
###end article-title 112
###begin article-title 113
Duration of nuclear NF-kappaB action regulated by reversible acetylation
###end article-title 113
###begin article-title 114
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation
###end article-title 114
###begin article-title 115
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency
###end article-title 115
###begin article-title 116
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Histone acetyltransferases regulate HIV-1 enhancer activity in vitro
###end article-title 116
###begin article-title 117
Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program
###end article-title 117
###begin article-title 118
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line
###end article-title 118
###begin article-title 119
Activation of PPARgamma coactivator-1 through transcription factor docking
###end article-title 119
###begin article-title 120
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway
###end article-title 120
###begin article-title 121
Condensation of monosubstituted isopropylidene malonates with mannich bases
###end article-title 121
###begin article-title 122
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases
###end article-title 122
###begin article-title 123
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
###end article-title 123
###begin article-title 124
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
###end article-title 124
###begin title 125
Abbreviations
###end title 125
###begin p 126
synthetic Tat protein carrying an acetylated lysine at position 50
###end p 126
###begin p 127
arginine-rich motif
###end p 127
###begin p 128
chloramphenicol acetyl transferase
###end p 128
###begin p 129
cyclin-dependent kinase 9
###end p 129
###begin p 130
cytomegalovirus
###end p 130
###begin p 131
dimethyl sulfoxide
###end p 131
###begin p 132
5,6-dichlorobenzimidazole riboside
###end p 132
###begin p 133
elongation factor 1alpha
###end p 133
###begin p 134
green fluorescent protein
###end p 134
###begin p 135
influenza hemagglutinin
###end p 135
###begin p 136
histone deacetylase
###end p 136
###begin p 137
###xml 0 28 <span type="species:ncbi:12721">human immunodeficiency virus</span>
human immunodeficiency virus
###end p 137
###begin p 138
immunoprecipitation
###end p 138
###begin p 139
long terminal repeat
###end p 139
###begin p 140
###xml 0 5 <span type="species:ncbi:10090">mouse</span>
mouse embryonic fibroblast
###end p 140
###begin p 141
myoblast determination protein
###end p 141
###begin p 142
nicotinamide adenine dinucleotide
###end p 142
###begin p 143
nuclear factor kappa B
###end p 143
###begin p 144
p300/CREB-binding protein-associated factor
###end p 144
###begin p 145
###xml 0 18 <span type="species:ncbi:11886">Rous sarcoma virus</span>
Rous sarcoma virus
###end p 145
###begin p 146
###xml 13 24 <span type="species:ncbi:3704">horseradish</span>
streptavidin-horseradish peroxidase conjugate
###end p 146
###begin p 147
standard error of the mean
###end p 147
###begin p 148
silent information regulator 2 protein
###end p 148
###begin p 149
sirtuin
###end p 149
###begin p 150
small interfering RNA
###end p 150
###begin p 151
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
trans-acting responsive element
###end p 151
###begin p 152
trichostatin A
###end p 152
###begin p 153
upstream activating sequence
###end p 153
###begin p 154
###xml 20 46 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
glycoprotein of the vesicular stomatitis virus
###end p 154
###begin p 155
Western blot
###end p 155
###begin title 156
Figures and Tables
###end title 156
###begin title 157
###xml 30 35 <span type="species:ncbi:9606">Human</span>
In Vitro Tat Deacetylation by Human SIRT Proteins
###end title 157
###begin p 158
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
(A) Scheme of Tat deacetylation assay with immunoprecipitated SIRT1-7 proteins. Expression vectors for FLAG-tagged SIRT proteins were transfected into HEK 293 cells, immunoprecipitated, and incubated with synthetic Tat (72 amino acids) carrying an N-terminal biotin label and an acetyl group at position 50 (AcTat) in the presence of NAD+. Immunoprecipitated material was also analyzed in a radioactive (3H) histone deacetylase assay using an H3 peptide as a substrate.
###end p 158
###begin p 159
(B) WB analysis of deacetylation reactions with antibodies specific for acetylated lysine 50 in Tat (alpha-AcTat), with SA-HRP, or with alpha-FLAG antibodies.
###end p 159
###begin p 160
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(C) WB of Tat deacetylation by immunoprecipitated SIRT1 in the presence or absence of NAD+, TSA, or nicotinamide (Nic).
###end p 160
###begin title 161
Physical Interaction between Tat and SIRT1
###end title 161
###begin p 162
(A) Immunoprecipitation (IP) and WB of FLAG-tagged Tat (Tat-FLAG) and HA-tagged SIRT1 (SIRT1-HA) after transfection of corresponding expression vectors (+) or empty vector controls (-) into HEK 293 cells.
###end p 162
###begin p 163
(B) The same experiments as in (A) performed with T7-tagged Tat and FLAG-tagged SIRT1, SIRT2, and SIRT6.
###end p 163
###begin p 164
###xml 191 197 <span type="species:ncbi:9986">rabbit</span>
(C) Coimmunoprecipitation of FLAG-tagged Tat with endogenous SIRT1 in HEK 293 cells transfected with the Tat expression vector or the empty vector control. IPs were performed with or without rabbit alpha-SIRT1 antibodies.
###end p 164
###begin p 165
(D) WB of recombinant SIRT1 protein after pulldown with synthetic biotinylated Tat or AcTat. Tat proteins were detected with antibodies specific for acetylated lysine 50 in the Tat ARM (alpha-AcTat) or SA-HRP.
###end p 165
###begin p 166
(E) Immunoprecipitation/WB of FLAG-tagged Tat or TatK50R and HA-tagged SIRT1. WT, wild type.
###end p 166
###begin title 167
SIRT1 Is a Positive Cofactor for Tat Transactivation
###end title 167
###begin p 168
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 171 174 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 206 209 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 311 314 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 339 342 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
(A) Cotransfection of SIRT1 or the catalytically inactive SIRT1 mutant SIRT1H363Y with the HIV LTR luciferase construct and increasing amounts of a Tat expression vector (RSV-Tat: 0, 2, 20, and 200 ng), an HIV LTR luciferase construct containing mutated binding sites for the transcription factor NF-kappaB and RSV-Tat (20 ng), or with an RSV-luciferase construct (200 ng) in HeLa cells. The average of three experiments is shown (+/- standard error of the mean [SEM]).
###end p 168
###begin p 169
(B) WB analysis of HeLa cells 72 h after transfection of siRNAs directed against SIRT1 or GL3 control siRNAs.
###end p 169
###begin p 170
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0030041-b36">36</xref>
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 82 85 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 93 96 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(C) Cotransfection of the HIV LTR luciferase construct with increasing amounts of CMV-Tat or CMV-TatK50R (0, 50, 100, 200, 400, and 800 ng) 48 h after transfection of double-stranded siRNAs directed against SIRT1 or GL3 control siRNAs in HeLa cells. Luciferase activity was measured 24 h after plasmid transfection and 72 h after siRNA transfection. Note that all luciferase reporter vectors used in this study are based on the pGL2 luciferase vector, which is not affected by GL3-specific siRNAs [36]. The average of three experiments is shown (+/- SEM).
###end p 170
###begin p 171
###xml 62 65 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(D) The transcriptional activity of increasing amounts of the CMV-luciferase reporter (0, 50, 100, 200, 400, and 800 ng) was similar in SIRT1 knockdown or GL3-treated control cells. The average of two experiments performed in duplicate is shown (+/- SEM).
###end p 171
###begin p 172
(E) WB of endogenous SIRT1 or actin 72 h after transfection of siRNA directed against SIRT1 or mutated SIRT1 siRNA.
###end p 172
###begin p 173
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 72 75 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(F) Cotransfection of the HIV LTR luciferase with increasing amounts of CMV-Tat (0, 2, 20, and 200 ng) in HeLa cells pretransfected with wild-type or mutant SIRT1 siRNA oligonucleotides as described in (C). WT, wild-type.
###end p 173
###begin title 174
###xml 53 56 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 41 47 <span type="species:ncbi:10090">Murine</span>
Impaired Tat Transcriptional Activity in Murine SIRT1-/- Cells
###end title 174
###begin p 175
###xml 128 131 128 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 139 142 139 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 50 53 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 267 270 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) Nuclear microinjection of HIV LTR luciferase, RSV-Tat, and a human cyclinT1-expressing construct into MEFs derived from SIRT+/+ or SIRT-/- mice. In all experiments, a fixed amount of DNA was injected by adding the empty vector control. Cells were coinjected with CMV-GFP, and the luciferase activity per GFP-positive cell was calculated. An average of two injections is shown.
###end p 175
###begin p 176
###xml 122 125 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 11 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 54 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
(B) The HIV LTR luciferase construct together with RSV-Tat and the cyclinT1-expressing construct were coinjected into SIRT-/- MEFs in the presence of increasing amounts of a plasmid expressing human SIRT1. The average of three experiments is shown (+/- SEM).
###end p 176
###begin p 177
###xml 220 223 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 23 28 <span type="species:ncbi:9606">human</span>
(C) Coinjection of the human SIRT1 expression vector together with the 5xUAS luciferase construct containing five Gal4 binding sites upstream of the thymidine kinase promoter and a Gal4-VP16 expression plasmid into SIRT1-/- MEFs. The average of three experiments is shown (+/- SEM).
###end p 177
###begin title 178
Transcriptional Activity of AcTat Depends on Deacetylation by SIRT1
###end title 178
###begin p 179
###xml 199 202 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 273 276 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) AcTat functions through TAR and cyclinT1 binding. Nuclear microinjection of increasing amounts of synthetic Tat or AcTat together with wild-type (wt TAR), TAR Deltabulge, or TAR Deltaloop mutant HIV LTR luciferase constructs into HeLa cells. Cells were coinjected with CMV-GFP, and luciferase activity was calculated per GFP-positive cell. An average of three experiments is shown (+/- SEM).
###end p 179
###begin p 180
###xml 109 112 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(B) AcTat transactivation requires CDK9. HeLa cells microinjected with Tat or AcTat (each 30 ng/mul) and the HIV LTR luciferase reporter were treated with increasing amounts of DRB, a known CDK9 inhibitor, for 4 h.
###end p 180
###begin p 181
###xml 103 106 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(C) AcTat transcriptional activity is inhibited by nicotinamide, but not TSA. HeLa cells injected with HIV LTR luciferase and increasing amounts of AcTat were treated with TSA (400 nM) or nicotinamide (5 mM) for 4 h. The average of two experiments is shown.
###end p 181
###begin p 182
###xml 167 170 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(D) SIRT1 is necessary for AcTat, but not Tat function. HeLa cells were transfected with siRNAs specific for SIRT1 or GL3 control siRNAs 48 h before microinjection of HIV LTR luciferase and Tat or AcTat (each 30 ng/mul). The average of three experiments is shown (+/- SEM).
###end p 182
###begin title 183
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Inhibition of HIV Gene Expression by a Small Molecule Inhibitor of SIRT1
###end title 183
###begin p 184
(A) In vitro histone deacetylation assays including recombinant SIRT1, radioactively labeled histone H3 peptide, and indicated concentrations of splitomicin or HR73. The average (+/- SEM) of two experiments performed in duplicate is shown for each point.
###end p 184
###begin p 185
(B) Chemical structures of splitomicin and its derivative HR73.
###end p 185
###begin p 186
###xml 47 50 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
###xml 79 82 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 110 113 <span type="species:ncbi:11886?0.2234143262858946">RSV</span>
(C) Inhibition of Tat transactivation by HR73. RSV-Tat (0, 20, and 200 ng) and HIV LTR luciferase (200 ng) or RSV-luciferase (200 ng) vectors were transfected into HeLa cells. Transfected cells were treated with indicated concentrations of HR73 or DMSO for 8 h.
###end p 186
###begin p 187
###xml 97 102 97 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NL4&#8211;3</sub>
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nef</italic>
###xml 18 21 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 183 186 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(D) Inhibition of HIV gene expression by HR73. GFP expression in Jurkat T cells infected with HIVNL4-3 containing the GFP open reading frame in place of the viral nef gene or with an HIV-based lentiviral vector expressing GFP from the heterologous EF-1alpha promoter. Treatment with HR73 (1 muM in DMSO) or DMSO was performed for 36 h after overnight infection. The average (+/- SEM) of four experiments is shown.
###end p 187
###begin p 188
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. MO conceived and designed the experiments. SP, AP, KK, and BLM performed the experiments. SP, EV, and MO analyzed the data. BJN, AD, CHE, PH, RF, MWM, HH, MJ, and EV contributed reagents/materials/analysis tools. SP, EV, and MO wrote the paper.
###end p 188
###begin p 189
###xml 94 97 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Citation: Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, et al. (2005) SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3(2): e41.
###end p 189

